FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

708822004: Secukinumab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2015. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3037500017 Secukinumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3037626016 Secukinumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
57511000195115 secukinumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
839651000172119 sécukinumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
72691000195112 Secukinumab de Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Secukinumab Is a Immunosuppressant (substance) true Inferred relationship Some
Secukinumab Is a agent d'anticorps monoclonal false Inferred relationship Some
Secukinumab Is a Monoclonal antibody true Inferred relationship Some
Secukinumab This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. A substance that modifies the immune response or the functioning of the immune system. true Inferred relationship Some
Secukinumab Is a anticorps monoclonal chimérique souris-humain d'isotype IgG false Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing secukinumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Secukinumab Inferred relationship Some 1
Secukinumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Secukinumab Inferred relationship Some 1
Product containing secukinumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Secukinumab Inferred relationship Some 1
Secukinumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Secukinumab Inferred relationship Some 1
Secukinumab therapy (procedure) Direct substance True Secukinumab Inferred relationship Some 1
Secukinumab 150 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Secukinumab Inferred relationship Some 1
Secukinumab 150 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Secukinumab Inferred relationship Some 1

This concept is not in any reference sets

Back to Start